Literature DB >> 11138790

The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS.

S J O'Brien1, J P Moore.   

Abstract

The pivotal discovery that two chemokine receptors, CCR5 and CXCR4, serve along with the T-cell receptor-interacting CD4 molecule as the principal co-receptors for HIV-1 entry stimulated a search for common genetic polymorphism in their genes which might affect the course of AIDS. Four mutational variants, CCR5-delta32, CCR5-P1, CCR2-641 and SDF1-3'A were discovered to play a regulatory role in HIV-1 infection, in the rate of progression to AIDS or both. Plausible physiological mechanisms to explain the population genetic association by these alleles have been advanced and are discussed critically here. Genetic ablation of AIDS progression by chemokine receptor and ligand gene variants has catalyzed development of novel therapies targeting the virus-co-receptor interaction. The functional and therapeutic implications of these AIDS restriction genes for disease progression and intervention are explored in this review.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11138790     DOI: 10.1034/j.1600-065x.2000.17710.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  74 in total

1.  Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic.

Authors:  E Gonzalez; R Dhanda; M Bamshad; S Mummidi; R Geevarghese; G Catano; S A Anderson; E A Walter; K T Stephan; M F Hammer; A Mangano; L Sen; R A Clark; S S Ahuja; M J Dolan; S K Ahuja
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

2.  HIV's response to a CCR5 inhibitor: I'd rather tighten than switch!

Authors:  Joshua M Farber; Edward A Berger
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-19       Impact factor: 11.205

3.  Blocking HIV-1 infection via CCR5 and CXCR4 receptors by acting in trans on the CCR2 chemokine receptor.

Authors:  José Miguel Rodríguez-Frade; Gustavo del Real; Antonio Serrano; Patricia Hernanz-Falcón; Silvia F Soriano; Antonio J Vila-Coro; Ana Martín de Ana; Pilar Lucas; Ignacio Prieto; Carlos Martínez-A; Mario Mellado
Journal:  EMBO J       Date:  2003-12-11       Impact factor: 11.598

4.  A strong signature of balancing selection in the 5' cis-regulatory region of CCR5.

Authors:  Michael J Bamshad; Srinivas Mummidi; Enrique Gonzalez; Seema S Ahuja; Diane M Dunn; W Scott Watkins; Stephen Wooding; Anne C Stone; Lynn B Jorde; Robert B Weiss; Sunil K Ahuja
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-29       Impact factor: 11.205

5.  Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.

Authors:  Douglas A Jabs
Journal:  Am J Ophthalmol       Date:  2010-12-18       Impact factor: 5.258

6.  Host and virus strain dependence in activation of human macrophages by human immunodeficiency virus type 1.

Authors:  Katarzyna Kazmierczak; Mary Jane Potash
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

7.  Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load.

Authors:  Leondios G Kostrikis; Giota Touloumi; Rose Karanicolas; Nikos Pantazis; Cleo Anastassopoulou; Anastasia Karafoulidou; James J Goedert; Angelos Hatzakis
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.

Authors:  Chi Young Ok; Ling Li; Zijun Y Xu-Monette; Carlo Visco; Alexander Tzankov; Ganiraju C Manyam; Santiago Montes-Moreno; Karen Dybkaer; Karen Dybaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Jiayu Chen; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; John P Farnen; Michael B Møller; Carlo E Bueso-Ramos; Roberto N Miranda; Jane N Winter; Miguel A Piris; L Jeffrey Medeiros; Ken H Young
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

9.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

Authors:  J M Strizki; S Xu; N E Wagner; L Wojcik; J Liu; Y Hou; M Endres; A Palani; S Shapiro; J W Clader; W J Greenlee; J R Tagat; S McCombie; K Cox; A B Fawzi; C C Chou; C Pugliese-Sivo; L Davies; M E Moreno; D D Ho; A Trkola; C A Stoddart; J P Moore; G R Reyes; B M Baroudy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

10.  APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia.

Authors:  Xia Jin; Andy Brooks; Huiyuan Chen; Ryan Bennett; Richard Reichman; Harold Smith
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.